(Q84540280)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610276%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

title

p53 immunohistochemistry in bladder cancer--a new approach to an old question (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610276%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

Peter J Goebell

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610276%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Susan G Groshen

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610276%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Bernd J Schmitz-Dräger

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610276%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

International Study-Initiative on Bladder Cancer (ISBC)

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610276%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

publication date

1 July 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610276%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610276%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610276%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

page(s)

377-388

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610276%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610276%20AND%20SRC:MED&resulttype=core&format=json

Awakening guardian angels: drugging the p53 pathway

7 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Biological markers in superficial bladder tumors and their prognostic significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Transcription regulation by mutant p53.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Mutant p53: an oncogenic transcription factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

p53 alterations in human cancer: more questions than answers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Statistical aspects of prognostic factor studies in oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Determination of clinical utility of tumor markers: a tumor marker utility grading system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Guidelines for development of diagnostic markers in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Statistical consideration for clinical biomarker research in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

p53 immunohistochemistry in bladder cancer. Combined analysis: a way to go?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Antigen retrieval immunohistochemistry: past, present, and future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Statistical problems with 'optimal' thresholds in studies of new prognostic factors in urology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

P53 expression, ploidy and progression in pT1 transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Immunohistological expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumour progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

p53 and Rb immunostaining in locally advanced bladder cancer: relation to prognostic variables and predictive value for the local response to radical radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Overexpression of p53 protein and its significance for recurrent progressive bladder tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Immunohistochemical determination of p53 overexpression. An easy and readily available method to identify progression in superficial bladder cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

p53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

p53 and erbB-2 protein overexpression are associated with early invasion and metastasis in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Expression of mdm-2 and p53 protein in transitional cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (Stage pTa/T1) bladder cancer: a prospective comparative study. The Finnbladder Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Urothelial tumorigenesis: a tale of divergent pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Bladder cancer subtypes defined by genomic alterations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Difficult decisions in urologic oncology: management of high-grade T1 transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Management of the first recurrence of T1G3 bladder cancer: does intravesical chemotherapy deserve a chance?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

High-risk, high-grade (T1G3) bladder cancer: models versus reality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Prognostic value of p53, Ki-67, microstaging and microvessel density in pT1G3 bladder tumors: creation of risk groups for progression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

Identification of clinically useful cancer prognostic factors: what are we missing?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.03.021

10.1016/J.UROLONC.2010.03.021

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610276%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference